Continuing foundational therapy in symptomatic HF: the key role of RAASi-based therapy
Video navigation menu
- RAASi therapy is part of GDMT for HF 00:25
- Target doses of RAASi therapy often not achieved 02:53
- Hyperkalemia can be a barrier to achieve target doses 04:49
- Importance of optimizing RAASi therapy in patients with HF 05:43
- Conclusions 08:18
In which range falls the proportion of patients with HF for whom hyperkalemia is a reason for not receiving target doses of MRA therapy?
- A. 2 - 5%
- B. 5 - 10%
- C. 10 - 15%
- D. 15 - 25%
This lecture by Shelley Zieroth, MD was part of the EBAC-accredited symposium "Breaking barriers in guideline-based RAASi therapy: Solving issues with hyperkalemia" at ESC Heart Failure in Prague, Czech Republic.
Shelley Zieroth, MD is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, and Director of the Heart Failure and Heart Transplant Clinics at St. Boniface Hospital, Winnipeg, CA. She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant received from AstraZeneca.